Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 迪哲医药是一家创新型生物医药企业，专注于恶性肿瘤、免疫性疾病领域创新疗法的研究、开发和商业化。公司坚持源头创新的研发理念，以推出全球首创药物（First-in-class）和具有突破性潜力的治疗方法为目标，旨在填补全球未被满足的临床需求。基于行业领先的转化科学和新药分子设计与筛选技术平台，公司已建立了五款具备全球竞争力的产品管线，两大领先产品处于全球关键性临床试验阶段，其中一款已获批上市。
Main Business 专注于恶性肿瘤、免疫性疾病领域创新疗法的研究、开发和商业化。
Legal Representative XIAOLIN ZHANG
Top Executives
董事长：XIAOLIN ZHANG
董事：吕大忠,RODOLPHE, PETER, ANDRé GRéPINET
独立董事：张昕,姜斌,王学恭,朱冠山
Top 5 Shareholder
Shareholder name Nature Holding Date
先进制造产业投资基金（有限合伙）限售股26.21%30/06/2024
AstraZeneca AB限售股26.21%30/06/2024
江苏无锡迪喆企业管理合伙企业（有限合伙）限售股13.82%30/06/2024
无锡高新区新动能产业发展基金（有限合伙）流通A股2.32%30/06/2024
Imagination V（HK）Limited流通A股2.29%30/06/2024
Company Secretary 吕洪斌
Solicitors 北京市中伦律师事务所
Auditors 普华永道中天会计师事务所（特殊普通合伙）
Tel No 021-61095757
Fax No 021-58387361
Website www.dizalpharma.com
Email IR@dizalpharma.com
Company Address
Register: 无锡市新吴区和风路26号汇融商务广场C栋404、405、416室
Office: 中国（上海）自由贸易试验区亮景路199、245号4幢 、无锡市新吴区和风路26号汇融商务广场C栋404、405、416室
Listing Date 10/12/2021
Shares Capital
Shares Capital: 415,653,120
Total A Share: 415,653,120
Listed A Share: 123,084,983
Non-tradable A Share: 292,568,137
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ -2.720
DPS(RMB)* --
NBV Per Share(RMB)* ¥ 2.079
Market Capitalization(RMB) 4.430B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.